	US 12,226,419 B2
	Topical formulation for a JAK inhibitor
Bhavnish Parikh, Avondale, PA (US); Bhavesh Shah, San Antonio, TX (US); and Krishnaswamy Yeleswaram, Landenberg, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed by Incyte Holdings Corporation, Wilmington, DE (US); and Incyte Corporation, Wilmington, DE (US)
Filed on Feb. 27, 2024, as Appl. No. 18/588,626.
Application 16/947,735 is a division of application No. 16/566,625, filed on Sep. 10, 2019, granted, now 10,758,543, issued on Sep. 1, 2020.
Application 18/588,626 is a continuation of application No. 17/541,439, filed on Dec. 3, 2021.
Application 17/541,439 is a continuation of application No. 16/948,408, filed on Sep. 17, 2020, granted, now 11,219,624, issued on Jan. 11, 2022.
Application 16/948,408 is a continuation of application No. 16/947,735, filed on Aug. 14, 2020, granted, now 10,869,870, issued on Dec. 22, 2020.
Application 16/566,625 is a continuation of application No. 14/714,820, filed on May 18, 2015, abandoned.
Application 14/714,820 is a continuation of application No. 13/112,370, filed on May 20, 2011, abandoned.
Claims priority of provisional application 61/347,132, filed on May 21, 2010.
Prior Publication US 2024/0245687 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 37/00 (2006.01); A01N 25/00 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/215 (2006.01); A61K 31/24 (2006.01); A61K 31/519 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01)]

20 Claims

1. A pharmaceutical formulation for topical skin application, wherein the formulation is an oil-in-water emulsion, the formulation comprising:

from 35% to 65% by weight of the formulation of water;

from 10% to 40% by weight of the formulation of a mixture of petrolatum, C_16-18fatty alcohols, mineral oil, a triglyceride, and a silicone oil;

from 2% to 6% by weight of the formulation of a mixture of a glyceryl fatty ester and a sorbitan fatty ester;

from 0.05% to 5% by weight of the formulation of a polysaccharide;

from 10% to 35% by weight of the formulation of a mixture of an alkylene glycol and a polyalkylene glycol; and

1.5% of (R)-3-cyclopentyl-3-[4-(7H-pyrrolo [2,3-d] pyrimidin-4-yl)-1H- pyrazol-1-yl]propanenitrile phosphoric acid salt by weight of the formulation on a free base basis.